Reporting owner · CIK 0001856094
Borgeson Blake
Visual SEC Form 4 history across 1 companies, 4 transactions and 4 filings.
DIRRECURSION PHARMACEUTICALS, INC.
Open-market mix
0%buys
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Jan 25
$0
Jan 26
−$959.2K
Feb 26
−$924K
Sep 26
−$100.2K
Transaction texture
Ownership and ticket size
Average P/S size$661.1K
Median P/S size$924K
Direct4
Indirect0
Sep 01, 2026sale
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
Latest transaction
sale at RECURSION PHARMACEUTICALS, INC. on Sep 01, 2026 valued at $100,200.
Review SEC filingLatest buy
No open-market insider purchase is available.
Latest sale
sale at RECURSION PHARMACEUTICALS, INC. on Sep 01, 2026 valued at $100,200.
Review SEC filingAssociated companies
Visual map of known reporting history
| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| RXRX | Borgeson Blake | DIR | sale10b5-1 | 30.0k | -$10.0M | S | 0.0% | 09/02 | 09/01 | |
| RXRX | Borgeson Blake | DIR | sale10b5-1 | 220k | -$92.4M | S | −17.8% | 02/06 | 02/03 | |
| RXRX | Borgeson Blake | DIR | sale10b5-1 | 220k | -$95.9M | S | — | 01/08 | 01/06 | |
| RXRX | Borgeson Blake | DIR | grant | 1.73k | $0 | A | — | 01/06/2025 | 01/02/2025 |
Borgeson Blake Insider Activity FAQ
SEC Form 4 context
Who is Borgeson Blake?
Borgeson Blake is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001856094.
Which companies has Borgeson Blake reported transactions for?
RECURSION PHARMACEUTICALS, INC.
When was Borgeson Blake's latest insider buy?
No open-market insider purchase is available for this period.
When was Borgeson Blake's latest insider sale?
sale at RECURSION PHARMACEUTICALS, INC. on Sep 01, 2026 valued at $100,200.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.